Zhejiang Teruisi Pharmaceutical Inc.   Report issue

For profit Phase 1 Phase 3
Founded: Zhejiang China (2010)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2018
NCT03882424
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Zhejiang Teruisi Pharmaceutical Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 8